Literature DB >> 16652153

DNA-binding independent cell death from a minimal proapoptotic region of E2F-1.

L A Bell1, J O'Prey, K M Ryan.   

Abstract

The ability to induce cell cycle progression while evading cell death is a defining characteristic of cancer. Deregulation of E2F is a common event in most human cancers. Paradoxically, this can lead to both cell cycle progression and apoptosis. Although the way in which E2F causes cell cycle progression is well characterized, the pathways by which E2F induces cell death are less well defined. Many of the known mechanisms through which E2F induces apoptosis occur through regulation of E2F target genes. However, mutants of E2F-1 that lack the transactivation domain are still able to induce cell death. To further investigate this activity, we refined a transactivation independent mutant to identify a minimal apoptotic domain. This revealed that only 75 amino acids from within the DNA-binding domain of E2F-1 is sufficient for cell death and that this activity is also present in the DNA-binding domains of E2F-2 and E2F-3. However, analysis of this domain from E2F-1 revealed it does not bind DNA and is consequently unable to transactivate, repress or de-repress E2F target genes. This provocative observation therefore defines a potential new mechanism of death from E2F and opens up new opportunities for inducing cell death in tumours for therapeutic gain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652153     DOI: 10.1038/sj.onc.1209580

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Cytoplasmic initiation of cisplatin cytotoxicity.

Authors:  Fang Yu; Judit Megyesi; Peter M Price
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-09

2.  Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus.

Authors:  Jorge G Gomez-Gutierrez; Xiao-Mei Rao; Heshan Sam Zhou; Kelly M McMasters
Journal:  Virology       Date:  2012-09-27       Impact factor: 3.616

3.  E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death.

Authors:  Céline Vuillier; Steven Lohard; Aurélie Fétiveau; Jennifer Allègre; Cémile Kayaci; Louise E King; Frédérique Braun; Sophie Barillé-Nion; Fabien Gautier; Laurence Dubrez; Andrew P Gilmore; Philippe P Juin; Laurent Maillet
Journal:  EMBO Rep       Date:  2017-12-12       Impact factor: 8.807

4.  Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivo.

Authors:  Jorge G Gomez-Gutierrez; Aracely Garcia-Garcia; Hongying Hao; Xiao-Mei Rao; Roberto Montes de Oca-Luna; Heshan S Zhou; Kelly M McMasters
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

5.  DRAM-1 encodes multiple isoforms that regulate autophagy.

Authors:  Li Yen Mah; Jim O'Prey; Alice D Baudot; Attje Hoekstra; Kevin M Ryan
Journal:  Autophagy       Date:  2012-01-01       Impact factor: 16.016

6.  Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1.

Authors:  G Vignir Helgason; Jim O'Prey; Kevin M Ryan
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

7.  Angiotensin II regulates activation of Bim via Rb/E2F1 during apoptosis: involvement of interaction between AMPKβ1/2 and Cdk4.

Authors:  Yong-Chul Kim; Regina M Day
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-01       Impact factor: 5.464

8.  Developing adenoviral vectors encoding therapeutic genes toxic to host cells: comparing binary and single-inducible vectors expressing truncated E2F-1.

Authors:  Jorge G Gomez-Gutierrez; Xiao-Mei Rao; Aracely Garcia-Garcia; Hongying Hao; Kelly M McMasters; H Sam Zhou
Journal:  Virology       Date:  2009-12-08       Impact factor: 3.616

9.  Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy.

Authors:  Jim O'Prey; Simon Wilkinson; Kevin M Ryan
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.

Authors:  Helen S Bell; Christine Dufes; Jim O'Prey; Diane Crighton; Daniele Bergamaschi; Xin Lu; Andreas G Schätzlein; Karen H Vousden; Kevin M Ryan
Journal:  J Clin Invest       Date:  2007-03-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.